This multi-institutional retrospective cohort study aimed to describe and analyze the overall clinical characteristics, therapeutic status and prognosis pattern of gastric cancer liver metastasis (GCLM) in China.
Study Type
OBSERVATIONAL
Enrollment
3,000
General Surgery Institute, China PLA General Hospital
Beijing, Beijing Municipality, China
1-year overall survival
The proportion (%) of gastric cancer liver metastasis patients that survived beyond one-year follow-up period.
Time frame: 2011/01/01-2020/12/31
3-year overall survival
The proportion (%) of gastric cancer liver metastasis patients that survived beyond three-year follow-up period.
Time frame: 2011/01/01-2021/12/31
5-year overall survival
The proportion (%) of gastric cancer liver metastasis patients that survived beyond five-year follow-up period.
Time frame: 2011/01/01-2021/12/31
The incidence of gastric cancer liver metastasis cases
The rate of gastric cancer liver metastasis cases divided by all gastric cancer cases in the study period.
Time frame: 2010/01/01-2019/12/31
The proportion for synchronous and metachronous liver metastases cases
The proportion (%) of synchronous or metachronous gastric cancer liver metastases cases in all gastric cancer cases
Time frame: 2010/01/01-2019/12/31
The survival of patients that recieved different therapeutic methods
The proportion (%) of patients under different therapies that survived beyond specific follow-up period.
Time frame: 2010/01/01-2019/12/31
The prognostic predictive value for patients with different C-GCLM classification
The proportion (%) of patients of different classification that survived beyond specific follow-up period.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 2010/01/01-2019/12/31